Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Senti Biosciences, Inc. (SNTI) is a clinical-stage biotechnology company pioneering gene circuit-engineered cell therapies for cancer treatment. This page serves as the definitive source for corporate announcements, clinical trial updates, and scientific advancements related to their synthetic biology platform.
Investors and researchers will find timely updates on SNTI's CAR-NK cell therapy programs targeting hematologic malignancies and solid tumors. The resource consolidates press releases covering clinical milestones, strategic collaborations, and regulatory developments while explaining complex biotechnological concepts in accessible language.
Key content includes updates on lead programs for acute myeloid leukemia (AML) and hepatocellular carcinoma (HCC), partnership announcements with biopharma innovators, and progress reports on their logic-gated Gene Circuit technology platform. All materials maintain rigorous adherence to factual reporting of verifiable company developments.
Bookmark this page for structured access to SNTI's latest scientific presentations, manufacturing updates, and peer-reviewed research findings. Check regularly for authoritative information directly from corporate communications and verified media sources.
Senti Biosciences (SNTI) announced it will host a conference call and webcast on Monday, April 28, 2025 at 8:30 AM ET to discuss new Phase 1 clinical data for SENTI-202 being presented at the American Association for Cancer Research (AACR) Annual Meeting.
The presentation will be led by CEO and Co-Founder Timothy Lu, MD, PhD, and President, Head of R&D and Chief Medical Officer Kanya Rajangam, MD, PhD. Participants can join via phone at (877) 524-8416 (domestic) or +1 (412) 902-1028 (international). The webcast will be available on the company's website and archived for 90 days.
Senti Biosciences (NASDAQ: SNTI) has released a Virtual Investor KOL Connect segment featuring a moderated discussion between two key experts in the field of leukemia research and treatment. The segment features Dr. Stephen Strickland, Director of Leukemia Research at Sarah Cannon Research Institute, and Dr. Kanya Rajangam, President, Head of R&D and Chief Medical Officer of Senti Bio.
The discussion focused on acute myeloid leukemia (AML), current treatment approaches, and unmet medical needs. The experts specifically highlighted Senti Bio's lead program, SENTI-202, and reviewed both clinical and preclinical data released by the company to date. The virtual segment is now available for viewing online.
Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotechnology company specializing in Gene Circuit platform for cell and gene therapies, has announced its participation in the Virtual Investor Closing Bell Series. The event is scheduled for Wednesday, April 23, 2025, at 4:00 PM ET.
The company's leadership team, including Timothy Lu, MD, PhD (CEO and Co-Founder) and Kanya Rajangam, MD, PhD (President, Head of R&D and Chief Medical Officer), will deliver a corporate overview followed by a live Q&A session. The presentation will be accessible through a live video webcast on the Events page of Senti Bio's website (www.sentibio.com), with a replay available for 90 days following the event.
Senti Biosciences (SNTI) has appointed James B. Trager, Ph.D. to its Scientific Advisory Board. Dr. Trager brings over 25 years of expertise in cellular therapy development and has contributed to nearly 50 publications, abstracts, and patents.
As former Chief Scientific Officer of Nkarta Therapeutics, he led multiple discovery assets through IND and developed CAR NK product opportunities. At Dendreon Pharmaceuticals, he served as Vice President of Research and Product Development, supporting sipuleucel-T development. His experience includes senior roles at Geron , where he contributed to human telomerase cloning.
Dr. Trager will support Senti Bio's development of Logic Gating technology and the SENTI-202 program for AML treatment. Throughout his career, he has managed over 100 scientists, engineers, and technicians in cell therapy development.
Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotechnology company developing next-generation cell and gene therapies, has announced its participation in the Webull Corporate Connect Service (CCS) platform. The company, which is advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with its lead candidate SENTI-202 in clinical development for acute myeloid leukemia (AML), aims to enhance transparency and communication with shareholders through this new platform.
Through Webull CCS, Senti Bio will share corporate content including company news, earnings reports, product updates, and presentations. CEO Timothy Lu emphasized the company's commitment to maintaining effective communication with shareholders and building market awareness as they continue their clinical execution.
Senti Biosciences (NASDAQ: SNTI) announced three abstract presentations at the upcoming AACR Annual Meeting 2025 (April 25-30, Chicago), showcasing new data from their lead product SENTI-202, a CAR NK cell therapy for relapsed/refractory acute myeloid leukemia (r/r AML).
The presentations include an oral minisymposium on clinical data, and two poster sessions focusing on correlative data and preclinical characterization of their Logic Gate technology. The preclinical data demonstrates that EMCN inhibitory CAR (NOT gate) effectively protects healthy bone marrow cells from on-target off-tumor toxicity in vivo.
Dr. Kanya Rajangam, President, Head of R&D and Chief Medical Officer, emphasized the potential of SENTI-202 for treating r/r AML and highlighted the broader applications of Logic Gating technology in oncology for selective cancer targeting while preserving healthy cells.
Senti Biosciences (NASDAQ: SNTI) has reported its Q4 and full-year 2024 financial results, highlighting significant clinical progress and financial developments. The company's lead product SENTI-202 showed promising initial Phase 1 results, with 2 out of 3 relapsed/refractory AML patients achieving MRD negative complete remission at the lowest dose level, maintaining remission as of March 2025.
The company substantially strengthened its financial position through a $47.6 million PIPE financing led by Celadon Partners, with participation from notable investors. The net proceeds of $45.1 million are expected to extend the company's runway into 2026. Additionally, Senti Bio received $1.5 million from CIRM, bringing total grant funding to $6.4 million.
Financial results show cash and cash equivalents of $48.3 million as of December 31, 2024. Q4 R&D expenses decreased to $7.8 million from $9.1 million year-over-year, while G&A expenses reduced to $8.4 million from $9.3 million. The company reported a Q4 net loss of $0.6 million ($0.67 per share) and a full-year 2024 net loss of $52.8 million ($12.03 per share).
Senti Biosciences (NASDAQ: SNTI) has appointed Feng Hsiung to its Board of Directors, effective March 7, 2025. Hsiung, who brings extensive business, finance, and investment expertise, will serve on the Board's Audit Committee. He is currently the Founder, Chief Investment Officer, and CEO of Acion Partners, which has a strategic partnership with KKR.
Additionally, the company granted stock options to three new employees, including 174,200 options to new CFO Jay Cross, with a per share exercise price of $3.52. The total grant comprises 202,700 shares under the company's 2022 Inducement Equity Plan, approved in accordance with NASDAQ Listing Rule 5635(c)(4).
Senti Biosciences (SNTI) has expanded its leadership team with two strategic appointments. Jay Cross will join as Chief Financial Officer on March 3, 2025, overseeing financial strategy, operations, and investor relations. Faraz Siddiqui joined in January 2025 as Senior Vice President of Technical Operations, managing process development, manufacturing, and supply chain.
CEO Timothy Lu expressed confidence that Cross's financial expertise and Siddiqui's technical operations leadership will support the company's clinical pipeline advancement, particularly for SENTI-202 and SENTI-301A. Cross brings extensive experience from Sonnet BioTherapeutics, where he led a capital campaign raising over $100 million, and from 20 years on Wall Street at firms including Chardan, SAC Capital, and Goldman Sachs.
Siddiqui contributes 27 years of biopharmaceutical experience, particularly in cell therapies, from previous roles at IGM Biosciences, Instil Bio, Kite Pharma, and Genentech, where he specialized in process development and manufacturing operations.
Senti Biosciences (NASDAQ: SNTI) has secured an additional $11.5 million in financing, comprising a $10 million private placement equity investment from Celadon Partners and $1.5 million from a CIRM grant. This additional funding brings the total PIPE financing round to $47.6 million, with participation from notable investors including NEA, Leaps by Bayer, and Nantahala Capital.
The company plans to use the proceeds to fund the development of its SENTI-202 program, manufacturing scale-up, research activities, and general corporate purposes. The funding has extended the company's cash runway guidance into 2026. The CIRM grant payment brings the total received from this source to $6.4 million out of the $8 million total grant announced in June 2024.
